Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Chemicals Press Releases.
Press releases published on May 7, 2025

Veeco Reports First Quarter 2025 Financial Results
First Quarter 2025 Highlights: Revenue of $167.3 million, compared with $174.5 million in the same period last year GAAP net income of $11.9 million, or $0.20 per diluted share, compared with $21.9 million, or $0.37 per diluted share in the same period …

Q3 2025 Results: Lesaka delivers on guidance, reaffirms FY2025 outlook and projects positive net income in FY2026
JOHANNESBURG, May 07, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the third quarter of fiscal 2025 (“Q3 2025”). Q3 2025 performance: Revenue of $135.7 million (ZAR 2.5 billion) was at the midpoint …

Texas Capital Announces Expansion of Corporate and Investment Banking Division
DALLAS, May 07, 2025 (GLOBE NEWSWIRE) -- Texas Capital Securities, a subsidiary of Texas Capital Bancshares, Inc. (NASDAQ: TCBI), today announced a significant expansion of the services offered by its Corporate and Investment Bank. The additions to …

Teekay Corporation Ltd. First Quarter 2025 Business Update; and Declares a Special Dividend
HAMILTON, Bermuda, May 07, 2025 (GLOBE NEWSWIRE) -- Teekay Corporation Ltd. (Teekay or the Company) (NYSE:TK) today reported a business update for the three months ended March 31, 2025. The business update and Teekay Group’s earnings presentation are …

Health Catalyst Reports First Quarter 2025 Results
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended …

Clarisil Pro Under Review: Proven Hearing Loss Support Supplement with Secret Navajo Remedy
New York, May 07, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why hearing loss is on the rise—and how environmental and lifestyle factors play a major role The most common causes of auditory decline, including inflammation, nutritional …

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined
SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first …

Sunrun Reports First Quarter 2025 Financial Results
Aggregate Subscriber Value of $1.2 billion in Q1, 23% growth year-over-year Contracted Net Value Creation of $164 million, or $0.72 per share, 104% growth year-over-year Cash Generation of $56 million in Q1, the fourth consecutive quarter of positive Cash …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty
ARLINGTON, Va., May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …

New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah
WEST JORDAN, Utah, May 07, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL) the nation’s leading builder of luxury homes, today announced the grand opening of the new model home at its Copperhaven by Toll Brothers community located in the heart of …

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …

FormFactor Announces Participation at Upcoming Conferences
LIVERMORE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) is pleased to announce its participation in the following investor conferences: B. Riley 25th Annual Investor Conference Location: The Ritz-Carlton, Marina del Rey Date: …

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …